Last 722.40
Change Today -11.30 / -1.54%
Volume 115.5K
As of 10:24 AM 12/25/14 All times are local (Market data is delayed by at least 15 minutes).

can fite biopharma ltd (CFBI) Snapshot

Open
$730.50
Previous Close
$733.70
Day High
$744.00
Day Low
$721.00
52 Week High
12/26/13 - $1,518
52 Week Low
11/18/14 - $445.50
Market Cap
154.0M
Average Volume 10 Days
213.4K
EPS TTM
$-2.64
Shares Outstanding
21.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CAN FITE BIOPHARMA LTD (CFBI)

can fite biopharma ltd (CFBI) Related Bloomberg News

View More Bloomberg News

can fite biopharma ltd (CFBI) Related Businessweek News

No Related Businessweek News Found

can fite biopharma ltd (CFBI) Details

Can-Fite BioPharma, Ltd., a clinical-stage biotechnology company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases. The company principally develops CF101 that is in Phase III study for the treatment of psoriasis, as well as completed Phase II study for the treatment of rheumatoid arthritis; completed Phase III study for the treatment of dry eye; completed Phase II study for the treatment of glaucoma; and initiating a Phase II study of CF101 for the treatment of uveitis. It also develops CF102, which is in Phase II study for the treatment of liver cancer; and CF602 that has completed pre-clinical trial for the treatment of inflammatory diseases. The company is headquartered in Petah-Tikva, Israel.

9 Employees
Last Reported Date: 04/24/14

can fite biopharma ltd (CFBI) Top Compensated Officers

Scientific Founder, Chief Executive Officer a...
Total Annual Compensation: 1.1M
Chief Operating & Financial Officer and Princ...
Total Annual Compensation: 782.0K
Vice President of Business Development
Total Annual Compensation: 736.0K
Compensation as of Fiscal Year 2013.

can fite biopharma ltd (CFBI) Key Developments

Can-Fite BioPharma Ltd. Doses First Patient in Global Phase II Liver Cancer Trial for CF102 Trial

Can-Fite BioPharma Ltd. announced that it has dosed the first patient in a Phase II trial for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. The Phase II randomized, double-blind, placebo controlled trial is to be conducted in the U.S., Europe and Israel with an estimated 78 patients to be enrolled. CF 102 is being evaluated for efficacy and safety as a second-line treatment for advanced HCC in subjects with Child-Pugh B who failed Nexavar as a first line treatment. The first patient was dosed at the study's Israeli site, the Rabin Medical Center. The primary endpoint of the study is overall patient survival. This Phase II study follows favorable results in Can-Fite's Phase I/II study, which was an open-label, dose-escalation study that evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of the orally administered CF102 in patients with advanced primary HCC. Data from that trial showed prolonged survival, stable disease in some patients, and regression of skin tumor metastases, as well as a favorable safety profile and lack of hepatotoxicity. The U.S. Food and Drug Administration has granted Orphan Drug Status to Can-Fite's CF 102 for this indication.

Can-Fite BioPharma Ltd. and OphthaLix Inc. Announce to Initiate the Enrollment of Patients to Second Cohort of the Phase II Clinical Study in Glaucoma

Can-Fite BioPharma Ltd. and its subsidiary, OphthaliX Inc., jointly announced the receipt of an approval from the regulatory authorities in Bulgaria to initiate the enrollment of patients to the second cohort of the Phase II clinical study in glaucoma. OphthaliX plans to conduct the study in two European countries, Bulgaria and Romania. The approval in Romania is expected shortly. In the first cohort of this study, patients were treated with 1 mg CF101 and placebo. Blinded results from this cohort showed that the drug had a favorable safety profile and was well tolerated. In the current cohort, the CF101 dose will be increased to 2 mg based on positive linear interim data in Can-Fite's Phase II/III Psoriasis study. The rationale to treat glaucoma patients with CF101 stems from data in another ophthalmic study showing that CF101 lowered the intraocular pressure (IOP) in patient eyes. Subjects will be randomized to receive 2 mg CF101 or matching placebo, given orally every 12 hours for 16 weeks. The study data will be released upon completion of the 2 mg dose treatment group, and is expected to be announced during the second half of 2015. OphthaliX has the exclusive rights for the use and development of CF101 in the field of ophthalmic diseases, which includes a US patent for the reduction of IOP that expires in 2030. Increased IOP is the most important and only modifiable risk factor for glaucoma.

Can-Fite BioPharma Ltd. to Initiate Development Program of its Next Generation Drug CF602

Can-Fite BioPharma Ltd. reported that it will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction. Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies. The company reported that it received positive pre-clinical data conducted in experimental animal models demonstrating that CF602 has improved sexual dysfunction in a dose dependent manner. CF602 is a novel A3 adenosine receptor allosteric modulator, enhancing the affinity of the natural ligand adenosine to its A3 adenosine receptor. Since adenosine accumulates in the microenvironment of the pathological cells, CF602 effect is a differential one and is believed not to affect normal body cells and tissues. The mechanism of action related to the improvement of sexual dysfunction stems out of the fact that adenosine, like nitric oxide, is a potent and short-lived vasorelaxant that functions via cAMP signaling to promote smooth muscle relaxation and penile erection. Can-Fite has a strong intellectual property position which includes an issued "composition of matter" patent and other pending patent applications protecting the use for sexual dysfunction. GlobalData estimates the value of the erectile dysfunction therapeutic market to be approximately $2.7 billion with few drugs in the market which include Viagra, Cialis and Levitra.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CFBI:IT 722.40 -11.30

CFBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CFBI.
View Industry Companies
 

Industry Analysis

CFBI

Industry Average

Valuation CFBI Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CAN FITE BIOPHARMA LTD, please visit www.canfite.co.il. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.